Event Participants
Executives
4 Pardeep Kumar Khanna (CFO), Abhay Raj Singh (SVP & Company Secretary), Kushal Kumar Rana (Director Works), Rakesh Mahajan (Finance Advisor & Strategic Head)
Analysts
10 Abhishek Kamdar (Value Plus Advisors), Abu Rafe (Wealth Catalyst), Jainam Ghelani (Svan Investments), Maulik Varia (360 ONE Capital), Nimesh Verma (AA&S Capital), Pahel Sharma (DD Capital), Santosh Khedekar (LGT Wealth), Santosh Shetty (LSG Capital), Saumya Raghuvanshi (Nirva Securities), Sheikh Mohammed (Individual Investor), Surabhi Sutaria (NV Alpha Fund Management), Vignesh Iyer (Sequent Investments)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹756 crores | +37% YoY (vs ₹551 crores Q1 FY26); driven by healthy demand across key products, improved capacity utilisation and better realizations |
| EBITDA | ₹111 crores | +60.7% YoY (vs ₹69.5 crores Q1 FY26); driven by operational leverage, capacity utilisation and product mix |
| EBITDA Margin | 14.6% | +220 bps YoY (vs 12.4% Q1 FY26); higher capacity utilisation, non-IBU pharma growth, export realizations |
| PAT | ₹64.5 crores | +89.9% YoY (vs ₹34 crores Q1 FY26); no one-offs, all operational efficiencies |
| PAT Margin | 8.4% | +230 bps YoY (vs 6.1% Q1 FY26) |
| Export Contribution | 28.5% of revenue | +410 bps YoY (vs 24.4% Q1 FY26); stronger international business across both segments |
| Pharma Segment Growth | +43% YoY | Broad-based across portfolio; capacity utilisation at 80-95% for most products except paracetamol |
| Non-IBU Pharma Contribution | 43% of pharma revenue | +700 bps YoY (vs 36% Q1 FY26); revenue +67% YoY, crossing ₹200 crore quarterly run-rate |
| R&D Investment (FY26) | ₹26 crores | Used for analytical equipment upgrades (XRD, LCMS, GCMS machines) for impurity profiling |
Geographic & Segment Commentary
Pharmaceutical Division: Revenue grew 43% YoY with non-ibuprofen products emerging as key growth driver, contributing 43% of pharma revenue vs 36% YoY. Non-IBU revenue grew 67% YoY crossing ₹200 crore quarterly run-rate, driven by Paracetamol, Clopidogrel, Pantoprazole, Metformin, Fenofibrate and Levetiracetam. All API products except paracetamol are operating at 80-95% capacity utilisation.
Chemical Division: Strong performance with improved realizations across ethyl acetate and acetic anhydride, supported by efficient raw material procurement and higher exports. Capacity enhancements across key product lines providing greater flexibility. Ethyl acetate and acetic anhydride prices spiked in March post US-Iran war, stabilised subsequently; management expects stable spreads.
International Business: Export contribution rose to 28.5% of revenue from 24.4% YoY. NMTA approval received for Clopidogrel in China; Ibuprofen previously approved. US FDA approvals in place for five products, with additional products awaiting approval through customer ANDA filings. CEP approvals available for all products.
Company-Specific & Strategic Commentary
API Portfolio Diversification: Strategy focused on building IOL as diversified integrated API platform; targeting 50% contribution from non-ibuprofen products in the near term. Management expects this mix shift to improve overall margin profile as export realizations for non-IBU products increase.
Capacity Expansion: Annual capex ~₹200 crores (60% expansion/new products, 40% infrastructure). Paracetamol capacity tripled from 3,600 MTPA to 10,800 MTPA, currently operating at 55% utilisation, expected to reach 70% by end FY27. New 6,000 MTPA Triacetin plant commenced production in May 2026; expected revenue potential of ~₹100 crores at steady state.
Backward Integration & R&D: R&D investments focused on analytical capabilities (XRD, LCMS, GCMS machines) for stringent impurity profiling. Company evaluating backward integration opportunities for new intermediates; proof of concept work underway. Metformin remains dependent on external DCD sourcing from China (not planned for integration).
Regulatory Expansion: Targeting regulated markets with NMPA China approval for Clopidogrel, US FDA approvals for five products, and CEP approvals across portfolio. Exploring additional opportunities in regulated markets based on customer requirements.
New Site Development: 101-acre land parcel received necessary approvals; statutory permissions in process. Product mix evaluation underway in R&D; first major projects unlikely to commission within current capex cycle.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth (FY27) | 15-20% | Based on healthy demand, pricing visibility and order book for coming quarters; management believes growth sustainable for full year |
| EBITDA Margin (FY27) | 14-15% | Q1 came in at 14.6% (top of range); sustainability driven by operational efficiencies, product mix; no major one-off inventory gains expected |
| Export Contribution (FY27) | 25-30% of revenue | Q1 achieved 28.5%; management targets ~30% with possible upside but maintains conservative communication stance |
| Revenue Growth (FY28) | 15-20% | Indicative, based on current scenario and plans; contingent on stable demand and input prices |
| EBITDA Margin (FY28) | 15-17% | Aspirational target subject to market conditions; management expects better margins with improved volumes and pricing scenario |
| Non-IBU Pharma Contribution (FY29) | 50-55% of API segment | Expect margins equivalent to ibuprofen; driven by diversification and export realizations |
| Triacetin Revenue Potential | ~₹100 crores/year at steady state | 6,000 MTPA capacity, commenced production May 2026; regulatory approval expected in 2-3 years |
Risks & Constraints
| Risk | Context |
|---|---|
| Raw Material Price Volatility | Input prices increased during the quarter; company passed on majority of cost increases to customers, but some big-customer contracts had pre-committed prices, causing sequential gross margin pressure. Management notes input/output prices now stabilised with no expectation of major near-term variation |
| Geopolitical/Supply Chain Disruption | US-Iran war impact led to sharp rise in ethyl acetate and acetic anhydride prices in March; prices have since stabilised. Company faces ongoing geopolitical uncertainty and supply chain challenges across raw materials |
| Export Concentration Volatility | Export contribution can fluctuate based on customer agreements - if most contracted quantities are dispatched in one quarter, subsequent quarters may see lower exports. This creates quarterly volatility even if annual targets are met |
| Paracetamol Regulatory Competition | Market demand historically weak; company operating at 55% utilisation of expanded capacity. Recovery expected to 70% by end FY27, but slower ramp-up could impact pharma segment growth |
| Customer Contract Pricing | Pre-committed prices with large customers for finished products create margin timing differences; full cost pass-through is not always immediate |
Q&A Highlights
Paracetamol Demand & Capacity
- Question: Given weak past demand, what's the current outlook for paracetamol? (Abu Rafe, Wealth Catalyst)
- Answer: Capacity tripled from 3,600 to 10,800 MTPA over two years; currently at 55% utilisation, expected to reach 70% by year-end. Paracetamol contributing significantly to non-IBU portfolio with traction in India and exports. (Abhay Raj Singh)
Ethyl Acetate & Acetic Anhydride Pricing
- Question: Impact of US-Iran war on pricing environment? (Abu Rafe, Wealth Catalyst)
- Answer: Prices increased substantially in March, stabilised over last month. Spread between raw materials and finished products expected to remain constant in coming quarters. (Unidentified Speaker)
Export Mix Target
- Question: Will exports move to 30%+ of revenue or maintain balanced domestic-export mix? (Pahel Sharma, DD Capital)
- Answer: Targeting 25-30% of revenue from exports this year; export number can fluctuate quarterly based on contracted customer dispatch schedules. (Abhay Raj Singh)
EBITDA Margin Drivers
- Question: What factors could sustain margins above guidance or cause moderation? (Pahel Sharma, DD Capital)
- Answer: Margin improvement driven by higher capacity utilisation, better product mix, operational efficiencies, stronger non-IBU API demand, and improved finished product (ISO) performance. (Pardeep Kumar Khanna)
Pharma Growth Split - Volume vs Realization
- Question: What portion of 43% pharma growth is volume vs realization? (Vignesh Iyer, Sequent Investments)
- Answer: Majority from volume growth driven by capacity utilisation (80-95% for most products except paracetamol), along with better export realizations; detailed split not disclosed. Regulated market mix has increased for non-IBU products. (Abhay Raj Singh)
Non-IBU Growth & 50% Milestone
- Question: What's driving non-IBU crossing ₹200 crore run-rate and regulated market split? (Surabhi Sutaria, NV Alpha)
- Answer: ~21-20% of non-IBU revenue from exports, majority from regulated markets. Key products: paracetamol, clopidogrel, pantoprazole, metformin, fenofibrate, levetiracetam. Company near achieving 50% IBU/50% non-IBU split. (Abhay Raj Singh)
Capex Allocation
- Question: Of ₹200-250 crore capex, how much is maintenance vs growth? Greenfield at new site? (Jainam Ghelani, Svan Investments)
- Answer: Annual capex ~₹200 crores; 60% toward expansion/new products, 40% toward infrastructure/efficiency improvements. (Unidentified Speaker)
Inventory Gains & One-offs
- Question: How much profitability attributable to one-time inventory gains from war-driven price surge? (Jainam Ghelani, Svan Investments)
- Answer: No inventory gain in this quarter (only ~10-15 days benefit at end of last quarter). Performance driven by capacity utilisation, product mix, operational efficiency, non-IBU growth and export realizations. (Abhay Raj Singh)
Non-IBU Margin Impact Timeline
- Question: When will non-IBU portfolio materially change overall pharma margins? (Santosh Khedekar, LGT Wealth)
- Answer: Near-term target of 50% non-IBU contribution with exports, combined with increased export realizations, will change bottom-line contribution. (Abhay Raj Singh)
R&D Commercial Opportunities
- Question: What commercial opportunities from ₹26 crore R&D investment in FY26? (Santosh Khedekar, LGT Wealth)
- Answer: Regular R&D expenses for ongoing development; funds allocated to high-end analytical equipment (XRD, LCMS, GCMS) for stringent impurity profile analysis. (Unidentified Speaker)
EBITDA Outperformance Attribution
- Question: How much of EBITDA growth was operating leverage vs product mix? (Saumya Raghuvanshi, Nirva Securities)
- Answer: EBITDA margin primarily from operational efficiencies of existing products with increased capacity utilisation; no major product mix change except more penetration in food market. Internal efficiencies are the primary driver. (Pardeep Kumar Khanna)
PAT Growth Drivers
- Question: Any one-offs contributing to 90% PAT growth? (Saumya Raghuvanshi, Nirva Securities)
- Answer: No extraordinary items; purely internal efficiencies and routine financial performance. (Pardeep Kumar Khanna)
FY29 Non-IBU Target
- Question: Target for non-IBU contribution by FY29 and margin impact? (Saumya Raghuvanshi, Nirva Securities)
- Answer: Expect non-IBU at 50-55% of API segment by FY29 with margins equivalent to ibuprofen. (Pardeep Kumar Khanna)
Demand Sustainability
- Question: Why this strong growth and will it sustain for 8-12 quarters? (Maulik Varia, 360 ONE Capital)
- Answer: Growth from higher volumes, better pricing of established products, new product growth; passed on increased costs to customers due to healthy demand domestically and in exports. Reasonable visibility into order book for coming quarter; growth expected sustainable for full year. FY28 guidance: 15-20% revenue growth, 15-17% EBITDA margin (indicative). (Pardeep Kumar Khanna, Abhay Raj Singh)
Sequential Gross Margin Decline
- Question: Was last quarter's gross margin higher due to inventory gains from war? (Maulik Varia, 360 ONE Capital)
- Answer: Yes, small inventory valuation benefit at end of March; this quarter input and finished prices both increased but margin impacted by pre-committed prices for large customers. Prices now stabilised - no major variation expected. (Unidentified Speaker)
Other Expenses Increase
- Question: What's driving higher other expenses sequentially? (Maulik Varia, 360 ONE Capital)
- Answer: Major components are energy and logistics costs with global pressure; company passing on major cost increases to customers, no material impact. (Pardeep Kumar Khanna)
US FDA & Regulatory Pipeline
- Question: Any new product filings or approvals in progress? (Maulik Varia, 360 ONE Capital)
- Answer: CEP approval available for all products; US FDA approval for five products; two-three products lined up through customer ANDA filings. NMPA China approved clopidogrel recently. (Abhay Raj Singh)
Ibuprofen Share Evolution
- Question: How will ibuprofen share evolve over next 3 years? (Nimesh Verma, AA&S Capital)
- Answer: IBU remains leadership product; company replicating the IBU success model in other products at scale. Growth expected to be broad-based across all product portfolio. (Abhay Raj Singh)
Backward Integration Potential
- Question: Any specific intermediates/KSMs being evaluated for backward integration? (Nimesh Verma, AA&S Capital)
- Answer: Working on different streams in R&D; will share details once proof of concept is ready. (Unidentified Speaker)
New Land Parcel Timeline
- Question: Will first projects on 101-acre land parcel commission within current capex cycle or FY28-29? (Nimesh Verma, AA&S Capital)
- Answer: Statutory permissions underway; product mix evaluation in R&D in parallel. Work will start once proof of concept is clear; probably not in this capex cycle. (Pardeep Kumar Khanna, Unidentified Speaker)
Chemical Segment Sustainability
- Question: Will chemical business maintain same performance? (Sheikh Mohammed, Individual Investor)
- Answer: Chemical EBITDA margin on upward trend with capacity increases in ethyl acetate and acetic anhydride; higher exports contributed. Expectation that performance will continue. (Pardeep Kumar Khanna)
CMO Segment Opportunity
- Question: Update on CMO space opportunity? (Sheikh Mohammed, Individual Investor)
- Answer: Working on this segment; will share details once proof of concept is ready. (Abhay Raj Singh)
Guidance Outperformance Potential
- Question: Can Q1 performance lead to outperforming previous full-year guidance? (Sheikh Mohammed, Individual Investor)
- Answer: Guidance remains in same line; current scenario suggests numbers may cross guidance, but company maintains conservative communication to avoid overpromising. Export number may be 28-35% - ~30% is the "mean" target. (Abhay Raj Singh)
Triacetin Capacity & Revenue
- Question: What's the triacetin capacity utilisation and steady-state revenue potential? (Abhishek Kamdar, Value Plus Advisors)
- Answer: Plant commissioned in May 2026 (one month production in Q1); capacity utilisation will increase with market penetration. Steady-state revenue potential ~₹100 crores/year. (Abhay Raj Singh, Pardeep Kumar Khanna)
Triacetin Inputs
- Question: Does triacetin use acetic anhydride as input? Captive consumption proportion? (Abhishek Kamdar, Value Plus Advisors)
- Answer: Triacetin uses acetic acid and glycerol - not acetic anhydride. (Abhay Raj Singh)
Backward Integration Gaps
- Question: Any significant raw materials/intermediates with external sourcing dependency? (Santosh Shetty, LSG Capital)
- Answer: Metformin is not integrated; dependent on DCD from China (most companies are, due to geographic availability). (Abhay Raj Singh)
Export Mix Benefits
- Question: Does higher export mix result in better product/customer mix or just higher volumes? (Santosh Shetty, LSG Capital)
- Answer: It's a mix of everything - product mix, operational efficiency, better realizations and customer reach; no single predominant factor. (Abhay Raj Singh)
Competitor Comparison (SMS Pharma)
- Question: Has IOL beaten SMS Pharma in ibuprofen manufacturing technology? (Sheikh Mohammed, Individual Investor)
- Answer: Company doesn't comment on competitors; confident in own strategy, manufacturing capabilities and operational efficiency. (Abhay Raj Singh)
Key Takeaway
IOL Chemicals delivered a strong Q1 FY27 with revenue at ₹756 crores (+37% YoY), EBITDA at ₹111 crores (+60.7%) with margins improving to 14.6%, and PAT at ₹64.5 crores (+89.9%). The quarter's outperformance was driven by broad-based growth across both pharma and chemical segments, underpinned by capacity utilisation above 80-95% across most products, strong export growth to 28.5% of revenue, and the non-ibuprofen API portfolio crossing ₹200 crore quarterly run-rate (43% of pharma revenue, up from 36% YoY). The strategic focus remains on building a diversified integrated API platform, with paracetamol capacity tripled to 10,800 MTPA (55% utilisation, targeting 70% by year-end) and exports into regulated markets expanding via the NMPA China approval for clopidogrel. Management has guided for FY27 revenue growth of 15-20%, EBITDA margins of 14-15%, and exports at 25-30%, with indication that current performance could exceed these targets. Indicative FY28 guidance points to 15-20% revenue growth and 15-17% EBITDA margins. Key watch points include raw material price stability post US-Iran war (now stabilised), paracetamol utilisation ramp-up, execution on the 101-acre greenfield site (unlikely to commission within current capex cycle), and the pace of non-IBU contribution moving toward the 50% milestone.